Cargando…

Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis

BACKGROUND: The prognostic value of preoperative fluorine-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG PET) scan for determining overall survival (OS) in breast cancer (BC) patients is controversial. AIM: To evaluate the OS predictive value of preoperative PET positivity after 15 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrin, Justine, Farid, Karim, Van Parijs, Hilde, Gorobets, Olena, Vinh-Hung, Vincent, Nguyen, Nam P, Djassemi, Navid, De Ridder, Mark, Everaert, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052070/
https://www.ncbi.nlm.nih.gov/pubmed/35582655
http://dx.doi.org/10.5306/wjco.v13.i4.287
_version_ 1784696706513764352
author Perrin, Justine
Farid, Karim
Van Parijs, Hilde
Gorobets, Olena
Vinh-Hung, Vincent
Nguyen, Nam P
Djassemi, Navid
De Ridder, Mark
Everaert, Hendrik
author_facet Perrin, Justine
Farid, Karim
Van Parijs, Hilde
Gorobets, Olena
Vinh-Hung, Vincent
Nguyen, Nam P
Djassemi, Navid
De Ridder, Mark
Everaert, Hendrik
author_sort Perrin, Justine
collection PubMed
description BACKGROUND: The prognostic value of preoperative fluorine-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG PET) scan for determining overall survival (OS) in breast cancer (BC) patients is controversial. AIM: To evaluate the OS predictive value of preoperative PET positivity after 15 years. METHODS: We performed a retrospective search of the Universitair Ziekenhuis Brussel patient database for nonmetastatic patients who underwent preoperative PET between 2002-2008. PET positivity was determined by anatomical region of interest (AROI) findings for breast and axillary, sternal, and distant sites. The prognostic role of PET was examined as a qualitative binary factor (positive vs negative status) and as a continuous variable [maximum standard uptake value (SUVmax)] in multivariate survival analyses using Cox proportional hazards models. Among the 104 identified patients who received PET, 36 were further analyzed for the SUVmax in the AROI. RESULTS: Poor OS within the 15-year study period was predicted by PET-positive status for axillary (P = 0.033), sternal (P = 0.033), and combined PET-axillary/sternal (P = 0.008) nodes. Poor disease-free survival was associated with PET-positive axillary status (P = 0.040) and combined axillary/sternal status (P = 0.023). Cox models confirmed the long-term prognostic value of combined PET-axillary/sternal status [hazard ratio (HR): 3.08, 95% confidence interval: 1.42-6.69]. SUVmax of ipsilateral breast and axilla as continuous covariates were significant predictors of long-term OS with HRs of 1.25 (P = 0.048) and 1.54 (P = 0.029), corresponding to relative increase in the risk of death of 25% and 54% per SUVmax unit, respectively. In addition, the ratio of the ipsilateral axillary SUVmax over the contralateral axillary SUVmax was the most significant OS predictor (P = 0.027), with 1.94 HR, indicating a two-fold relative increase of mortality risk. CONCLUSION: Preoperative PET is valuable for prediction of long-term survival. Ipsilateral axillary SUVmax ratio over the uninvolved side represents a new prognostic finding that warrants further investigation.
format Online
Article
Text
id pubmed-9052070
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-90520702022-05-16 Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis Perrin, Justine Farid, Karim Van Parijs, Hilde Gorobets, Olena Vinh-Hung, Vincent Nguyen, Nam P Djassemi, Navid De Ridder, Mark Everaert, Hendrik World J Clin Oncol Retrospective Study BACKGROUND: The prognostic value of preoperative fluorine-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG PET) scan for determining overall survival (OS) in breast cancer (BC) patients is controversial. AIM: To evaluate the OS predictive value of preoperative PET positivity after 15 years. METHODS: We performed a retrospective search of the Universitair Ziekenhuis Brussel patient database for nonmetastatic patients who underwent preoperative PET between 2002-2008. PET positivity was determined by anatomical region of interest (AROI) findings for breast and axillary, sternal, and distant sites. The prognostic role of PET was examined as a qualitative binary factor (positive vs negative status) and as a continuous variable [maximum standard uptake value (SUVmax)] in multivariate survival analyses using Cox proportional hazards models. Among the 104 identified patients who received PET, 36 were further analyzed for the SUVmax in the AROI. RESULTS: Poor OS within the 15-year study period was predicted by PET-positive status for axillary (P = 0.033), sternal (P = 0.033), and combined PET-axillary/sternal (P = 0.008) nodes. Poor disease-free survival was associated with PET-positive axillary status (P = 0.040) and combined axillary/sternal status (P = 0.023). Cox models confirmed the long-term prognostic value of combined PET-axillary/sternal status [hazard ratio (HR): 3.08, 95% confidence interval: 1.42-6.69]. SUVmax of ipsilateral breast and axilla as continuous covariates were significant predictors of long-term OS with HRs of 1.25 (P = 0.048) and 1.54 (P = 0.029), corresponding to relative increase in the risk of death of 25% and 54% per SUVmax unit, respectively. In addition, the ratio of the ipsilateral axillary SUVmax over the contralateral axillary SUVmax was the most significant OS predictor (P = 0.027), with 1.94 HR, indicating a two-fold relative increase of mortality risk. CONCLUSION: Preoperative PET is valuable for prediction of long-term survival. Ipsilateral axillary SUVmax ratio over the uninvolved side represents a new prognostic finding that warrants further investigation. Baishideng Publishing Group Inc 2022-04-24 2022-04-24 /pmc/articles/PMC9052070/ /pubmed/35582655 http://dx.doi.org/10.5306/wjco.v13.i4.287 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Retrospective Study
Perrin, Justine
Farid, Karim
Van Parijs, Hilde
Gorobets, Olena
Vinh-Hung, Vincent
Nguyen, Nam P
Djassemi, Navid
De Ridder, Mark
Everaert, Hendrik
Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis
title Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis
title_full Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis
title_fullStr Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis
title_full_unstemmed Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis
title_short Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis
title_sort is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? a 15-year overall survival analysis
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052070/
https://www.ncbi.nlm.nih.gov/pubmed/35582655
http://dx.doi.org/10.5306/wjco.v13.i4.287
work_keys_str_mv AT perrinjustine isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT faridkarim isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT vanparijshilde isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT gorobetsolena isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT vinhhungvincent isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT nguyennamp isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT djasseminavid isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT deriddermark isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis
AT everaerthendrik isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis